2 patents currently held
29 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Feb 2033. from the record
Of the 29 now held by other companies, 9 name Universite Paris Saclay as their current owner, and 20 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2033
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends no later than Feb 2033 · Medium confidence
Also notable
Ends Jul 2036 · High confidence
Methods and Pharmaceutical Compositions for the Treatment and the Prevention of Cardiomyopathy Due to Friedreich Ataxia
US 10,337,027
The most cited patent in this portfolio, cited by 15 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2033. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Novel Adamantane and Memantine Derivatives as Peripheral Nmda Receptor Antagonists
US 10,538,482
Granted 2020. Computed term ends 2036.
Formerly held, still cited
Notable
Ends Jun 2037 · High confidence
Cited by 20 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2037.
now held by PML Screening, LLC
Also notable
Ends Mar 2038 · High confidence
The newest of the three, granted 2023. It anchors the portfolio to 2038, later than anything else here.
now held by Universite Paris-Saclay
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 2, 2027The maintenance fee for Methods and Pharmaceutical Compositions for the Treatment and the Prevention of Cardiomyopathy Due to Friedreich Ataxia (US 10,337,027) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
- 1 fee due Jul 21, 2027The maintenance fee for Novel Adamantane and Memantine Derivatives as Peripheral Nmda Receptor Antagonists (US 10,538,482) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,337,027 | Methods and Pharmaceutical Compositions for the Treatment and the Prevention of Cardiomyopathy Due to Friedreich Ataxia held by Institut National de la Santé et de la Recherche Médicale (Inserm), Université Paris-Sud XI and Assistance Publique - Hôpitaux de Paris (Aphp) In force · Medium confidence | In force | Medium confidence | |
| US 10,538,482 | Novel Adamantane and Memantine Derivatives as Peripheral Nmda Receptor Antagonists held by Institut National de la Santé et de la Recherche Médicale (Inserm), Assistance Publique-Hopitaux de Paris, Centre National de la Recherche Scientifique (CNRS) and Université Paris-Sud In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 29 patents in force now held by others · 6 patents ended · 6 applications pending · 14 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed